MedTrace Logo

Biological Markers of Treatment Response to Repetitive Transcranial Magnetic Stimulation for Depression

NCT02438748 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 310

Last updated 2020-11-04

No results posted yet for this study

Summary

The main objective of this study is to determine whether biological stress markers (Oxidized Phosphatidylcholines and Oxylipins) in the blood can be used to predict the efficacy of rTMS in the treatment of major depressive disorder (MDD). It is our goal to identify biomarkers that may be used to determine which patients will benefit from rTMS treatment. A second objective of this study is to measure any changes in stress markers that occur across the course of rTMS therapy.

Conditions

  • Oxidative Stress

Interventions

DEVICE

Repetitive Transcranial Magnetic Stimulation

A non-invasive method of brain stimulation.

Sponsors & Collaborators

  • University of Manitoba

    lead OTHER

Principal Investigators

  • Mandana Modirrousta, MD PhD FRCPC · University of Manitoba

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-05-31
Primary Completion
2022-01-31
Completion
2022-05-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02438748 on ClinicalTrials.gov